Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

New York City sues drug companies over opioid epidemic

Published 01/23/2018, 02:04 PM
Updated 01/23/2018, 02:04 PM
© Reuters. New York City Mayor Bill de Blasio delivers remarks at his 2018 Inaugural Ceremony at City Hall in Manhattan, New York

By Jonathan Stempel and Nate Raymond

NEW YORK (Reuters) - New York City on Tuesday sued eight companies that make or distribute prescription opioids, blaming them for fuelling a deadly epidemic afflicting the most populous U.S. city.

Mayor Bill de Blasio said the lawsuit sought $500 million of damages to help fight the crisis, which kills more people in the city annually than homicides and car accidents combined, including more than 1,100 from opioid-induced overdoses in 2016.

"Big Pharma helped to fuel this epidemic by deceptively peddling these dangerous drugs and hooking millions of Americans in exchange for profit," de Blasio said in a statement.

The defendants include manufacturers Allergan Plc (N:AGN), Endo International Plc (O:ENDP), Johnson & Johnson (N:JNJ), Purdue Pharma LP and Teva Pharmaceutical (NYSE:TEVA) Industries Ltd (TA:TEVA), and distributors AmerisourceBergen Corp (N:ABC), Cardinal Health Inc (N:CAH) and McKesson Corp (N:MCK).

All were accused in the city's complaint of creating a public nuisance, and the distributors were accused of negligence.

Allergan, Endo, J&J, Purdue, Teva, AmerisourceBergen and McKesson in separate statements emphasized the importance of using opioids safely.

Endo, J&J and Purdue also denied the city's allegations, while McKesson declined to comment on the lawsuit. Cardinal Health did not immediately respond to requests for comment.

New York City, whose population is about 8.54 million, joined a long list of U.S. states and municipalities to sue drug companies over opioid abuse, which U.S. President Donald Trump has called a national public health emergency.

Opioids, including prescription painkillers and heroin, played a role in 42,249 U.S. deaths in 2016, up 28 percent from 2015 and 47 percent from 2014, according to the U.S. Centers for Disease Control and Prevention.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

In its complaint filed in state court in Manhattan, New York accused manufacturers of having for two decades misled consumers into believing that prescription opioids were safe to treat chronic non-cancer pain, with minimal risk of addiction.

The city also said distributors fueled abuse through oversupply, including a failure to identify suspicious orders and report them to authorities, contributing to an illegal secondary market.

Prescription opioids, such as Purdue's OxyContin and Endo's Percocet, are regulated as controlled substances.

New York City said roughly 2.5 million to 2.7 million opioid prescriptions were filled there each year from 2014 to 2016.

The case is City of New York v Purdue Pharma LP et al, New York State Supreme Court, New York County, No. 450133/2018.

Latest comments

typical dems...blame a corporation instead of their own failed policies. A lawsuit in lieu of a tax increase, interesting approach, i hope they fail
The same companies that are so very generous to members of congress. What nonsense.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.